Tauroursodeoxycholic acid improves viability of artificial RBCs

Area of Science:

• Biochemistry
• Hematology
• Stem Cell Biology

Background:

• Tauroursodeoxycholic acid (TUDCA) is recognized for its anti-apoptotic properties via the Bax pathway.
• TUDCA also promotes neovascularization by enhancing stem cell mobilization and differentiation.

Purpose of the Study:

• To investigate the impact of TUDCA on erythropoiesis in hematopoietic stem cells (HSCs).
• To evaluate TUDCA's effect on cell number, viability, morphology, and erythroid marker expression during HSC erythropoiesis.

Main Methods:

• Erythropoiesis of CD34(+) HSCs was analyzed across four distinct phases.
• Key parameters assessed included total cell number, viable cell count, cell viability, morphology, and erythroid marker expression.

Main Results:

• TUDCA did not significantly alter cell viability in phases I and II compared to controls.
• TUDCA treatment significantly increased viable cell numbers and viability in phases III and IV.
• A higher proportion of immature erythroid cells was observed in TUDCA-treated cultures until phase III, with all developing into mature RBCs.
• The final number and viability of red blood cells (RBCs) were significantly higher in TUDCA-treated groups.

Conclusions:

• TUDCA enhances erythropoiesis, leading to increased RBC production and viability.
• TUDCA shows potential as a novel additive for improving artificial RBC production protocols.